Innovation Pharmaceuticals Inc
OTC:IPIX
Innovation Pharmaceuticals Inc
Operating Income
Innovation Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innovation Pharmaceuticals Inc
OTC:IPIX
|
Operating Income
-$2.4m
|
CAGR 3-Years
21%
|
CAGR 5-Years
27%
|
CAGR 10-Years
4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$11B
|
CAGR 3-Years
3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.1B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
Innovation Pharmaceuticals Inc
Glance View
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is engaged in developing therapies with anti-inflammatory, antibiotic, antiviral, dermatology and oncology applications. The firm owns the right to numerous drug compounds, including Brilacidin, its lead drug in a class of compounds known as defensin-mimetics and Kevetrin (thioureidobutyronitrile), which is its lead anti-cancer compound. The firm's clinical trials focused on evaluating its drug candidates, including Kevetrin for the treatment of cancers and Brilacidin for treatments of Acute Bacterial Skin and Skin Structure Infection (ABSSSI), prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative colitis. The firm is focused on developing small molecule therapies to treat diseases in the areas of inflammatory diseases, cancer, dermatology and anti-infectives.
See Also
What is Innovation Pharmaceuticals Inc's Operating Income?
Operating Income
-2.4m
USD
Based on the financial report for Sep 30, 2023, Innovation Pharmaceuticals Inc's Operating Income amounts to -2.4m USD.
What is Innovation Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
4%
Over the last year, the Operating Income growth was 61%. The average annual Operating Income growth rates for Innovation Pharmaceuticals Inc have been 21% over the past three years , 27% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet